Pay in 4 interest-free payments of $27.23 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
is a next-generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity
is an antifungal lipopeptide that acts by inhibiting the synthesis of β-(1
GSK2801 was used at 10 µM final concentration in vitro and in cellular assays
Chemical Name: 2-[(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1
InChiKey: LAZPBGZRMVRFKY-HNCPQSOCSA-N
Emricasan Catalog No.:M10978-10 is a next-generation proteasome inhibitorEmricasan, also known as IDN 6556 and PF 03491390, is a first in class caspase inhibitor in clinical trials for the treatment of liver diseases. Emricasan (IDN 6556) decreases liver injury and fibrosis in a murine model of non alcoholic steatohepatitis. IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Oral IDN 6556 may lower aminotransferase activity in patients with chronic hepatitis C. Orally administered
US$ 114.99
US$ 849.50
US$ 24.95
US$ 147.50